Education
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (TSE:HLS)
TSX:HLS
Total Valuation
HLS Therapeutics Inc has a market cap or net worth of C$153.55M. The enterprise value is C$211.13M.
Market CapC$153.55M
Enterprise ValueC$211.13M
Share Statistics
HLS Therapeutics Inc has 31,273,682 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31,273,682
Owned by Insiders0.46%
Owned by Institutions1.60%
Financial Efficiency
HLS Therapeutics Inc’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -6.80%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-6.80%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee615.42K
Profits Per Employee-213.64K
Employee Count92
Asset Turnover0.35
Inventory Turnover0.99
Valuation Ratios
The current PE Ratio of HLS Therapeutics Inc is ―. HLS Therapeutics Inc’s PEG ratio is 0.16.
PE Ratio―
PS Ratio1.54
PB Ratio1.22
Price to Fair Value1.22
Price to FCF10.89
Price to Operating Cash Flow8.42
PEG Ratio0.16
Income Statement
In the last 12 months, HLS Therapeutics Inc had revenue of 56.62M and earned -19.66M in profits. Earnings per share was -0.62.
Revenue56.62M
Gross Profit47.62M
Operating Income-7.69M
Pretax Income-15.58M
Net Income-19.66M
EBITDA17.22M
Earnings Per Share (EPS)-0.62
Cash Flow
In the last 12 months, operating cash flow was 13.83M and capital expenditures -1.40M, giving a free cash flow of 12.43M billion.
Operating Cash Flow13.83M
Free Cash Flow12.43M
Free Cash Flow per Share0.40
Dividends & Yields
HLS Therapeutics Inc pays an annual dividend of C$0.05, resulting in a dividend yield of ―
Dividend Per ShareC$0.05
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.84
52-Week Price Change32.08%
50-Day Moving Average5.20
200-Day Moving Average4.95
Relative Strength Index (RSI)41.98
Average Volume (3m)19.90K
Important Dates
HLS Therapeutics Inc upcoming earnings date is Mar 12, 2026, Before Open (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
HLS Therapeutics Inc as a current ratio of 1.57, with Debt / Equity ratio of 83.49%
Current Ratio1.57
Quick Ratio1.17
Debt to Market Cap0.75
Net Debt to EBITDA2.85
Interest Coverage Ratio-0.76
Taxes
In the past 12 months, HLS Therapeutics Inc has paid 4.07M in taxes.
Income Tax4.07M
Effective Tax Rate-0.26
Enterprise Valuation
HLS Therapeutics Inc EV to EBITDA ratio is 7.90, with an EV/FCF ratio of 17.02.
EV to Sales2.40
EV to EBITDA7.90
EV to Free Cash Flow17.02
EV to Operating Cash Flow16.99
Balance Sheet
HLS Therapeutics Inc has C$10.78M in cash and marketable securities with C$54.09M in debt, giving a net cash position of -C$43.31M billion.
Cash & Marketable SecuritiesC$10.78M
Total DebtC$54.09M
Net Cash-C$43.31M
Net Cash Per Share-C$1.38
Tangible Book Value Per Share-C$1.59
Margins
Gross margin is 82.59%, with operating margin of -13.57%, and net profit margin of -34.71%.
Gross Margin82.59%
Operating Margin-13.57%
Pretax Margin-27.52%
Net Profit Margin-34.71%
EBITDA Margin30.41%
EBIT Margin-9.71%
Analyst Forecast
The average price target for HLS Therapeutics Inc is C$7.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$7.25
Price Target Upside47.96% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast0.73%
EPS Growth Forecast33.51%